Caris Life Sciences validated a new AI‑derived signature that predicts temozolomide benefit in glioblastoma patients. The validation was published in Neuro‑Oncology Advances and involved a cohort of more than 5,800 GBM patients. The model was trained on 5,841 patients and tested prospectively in over 3,400 cases.
The signature infers MGMT promoter methylation status from whole‑exome and whole‑transcriptome sequencing data, achieving high concordance with the standard pyrosequencing assay. By stratifying patients into distinct survival groups, the signature identified higher scores as associated with significantly longer overall survival among those treated with temozolomide.
This milestone expands Caris’ AI‑Insights portfolio, offering clinicians a non‑invasive biomarker that can guide temozolomide use in IDH‑wild‑type glioblastoma. The ability to predict treatment benefit from NGS data could improve the precision of therapy selection and enhance patient outcomes.
"The Caris AI Insights signature for GBM showcases Caris' advanced AI capabilities in our pursuit of improving cancer patient outcomes," said David Spetzler, president of Caris Life Sciences. The validation reinforces Caris’ position as a leader in comprehensive genomic profiling and AI‑driven oncology solutions.
The study’s peer‑reviewed results underscore the potential for AI to complement traditional biomarker testing and support more personalized treatment strategies in a disease with limited therapeutic options.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.